logo

For the Inventor, By the Inventor

Cambridge, MA, United States of America

Tomoko Nakayama

This inventor holds 8 USPTO granted patents and 1 published patent application. Top assignees: Alnylam Pharmaceuticals, Inc., ETH Zurich. Active years: 2012-2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tomoko Nakayama. Retrieved from https://idiyas.com/inventor/tomoko-nakayama

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 8 

% Patents Active = 100.0

Average Co-Inventor Count = 4.1

ph-index = 4

Forward Citations = 32(Granted Patents)


Company Filing History:

goldMedal8 out of 465 
 
Alnylam Pharmaceuticals, Inc.
 patents
silverMedal2 out of 555 
 
ETH Zurich
 patents
where one patent can have more than one assignee

Years Active: 2012-2016

Loading Chart...
8 patents (USPTO):Explore Patents
1. 9506067 - Compositions and methods for inhibiting expression of the HAMP gene (2016-11-29),
2. 9090895 - Compositions and methods for inhibiting expression of the HAMP gene (2015-07-28),
3. 8791250 - Compositions and methods for inhibiting expression of the HAMP gene (2014-07-29),
4. 8470799 - Compositions and methods for inhibiting expression of the HAMP gene (2013-06-25),
5. 8324366 - Compositions and methods for delivering RNAI using lipoproteins (2012-12-04),
6. 8268799 - Compositions and methods for inhibiting expression of the HAMP gene (2012-09-18),
7. 8163711 - Compositions and methods for inhibiting expression of the HAMP gene (2012-04-24),
8. 8148344 - Compositions and methods for mediating RNAi in vivo (2012-04-03),

Title: The Innovative Journey of Tomoko Nakayama in Medical Science

Introduction: Tomoko Nakayama, a pioneering inventor based in Cambridge, MA, has made significant contributions in the field of medical science with a total of 8 patents to her name. Her groundbreaking work focuses on inhibiting the expression of the HAMP gene, offering promising solutions for treating diseases associated with its overexpression.

Latest Patents: One of Nakayama's recent patents involves compositions and methods for inhibiting the expression of the HAMP gene. This invention revolves around a double-stranded ribonucleic acid (dsRNA) designed to target the HAMP gene's expression. The patent encompasses a pharmaceutical composition containing the dsRNA along with a pharmaceutically acceptable carrier, demonstrating potential in disease treatment linked to HAMP gene expression.

Career Highlights: Nakayama's illustrious career includes stints at renowned companies such as Alnylam Pharmaceuticals, Inc. and ETH Zurich. Her innovative spirit and dedication to medical advancements have led to the development of novel technologies aimed at combatting genetic disorders and diseases at their core molecular level.

Collaborations: Throughout her career, Nakayama has collaborated with esteemed professionals in the field, including Anke Geick and Pamela Tan. Together, they have synergized their expertise to push the boundaries of medical research and pave the way for transformative solutions in genetic medicine.

Conclusion: Tomoko Nakayama's trailblazing journey as an inventor in the realm of medical science exemplifies her commitment to driving innovation and fostering breakthroughs in disease treatment. With a strong focus on genetic therapies, Nakayama's patents and collaborations stand as a testament to her visionary approach in revolutionizing the healthcare landscape.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…